Search Results - pommier

6 Results

Sort By:

Oxynitidine Derivatives Useful as Inhibitors of Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) for Treating Cancer

Summary: The National Cancer Institute (NCI) is actively seeking potential licensees and/or co-development research collaboration partners interested in advancing oxynitidine derivatives as novel inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1) for cancer treatment. These TOPI and TDP1 inhibitors, when administered...

Published: 9/18/2024 | Inventor(s): Yves Pommier, Lin-kun An, Keli Agama, Evgeny Kiselev, Azhar Ravji

Keywords(s): Benzophenanthridine Derivatives, Benzophenanthridinone, Camptothecin, Dihydrobenzophenanthridine, IRINOTECAN, Oxynitidine, Pommier, Tdp1, TOP1, Topoisomerase 1B, Topotecan, Tyrosyl-DNA Phosphodiesterase 1

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Topoisomerase III (TOP3) Inhibitors as Antiviral and Anticancer Compounds based on Bisacridines

Abstract: Topoisomerase 3B (TOP3B) is the only topoisomerase that can act on RNA as well as DNA. Thus, it is a target of interest for the development of cancer therapies and RNA viral infection therapies. TOP3B is not an essential gene for carcinogenesis, but a subset of cancer cells with pre-existing genome instability are particularly vulnerable to...

Published: 4/8/2024 | Inventor(s): Yves Pommier, Sourav Saha, Wenjie Wang, Shar-yin Huang

Keywords(s): Bisacridines, CANCER, Pommier, SARS-CoV-2, TOP, TOP3, TOP3 Inhibitor, TOPOISOMERASE, Topoisomerase III, Topoisomerase Inhibitor, viral infection

Category(s): TherapeuticArea > Infectious Disease, Collaboration Sought > Licensing, Application > Therapeutics, Collaboration Sought > Collaboration, TherapeuticArea > Oncology

Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection

Abstract: Topoisomerase poisons, such as quinolone antibiotics, are widely used as anticancer drugs and antibiotics. Quinolone antibiotics act by trapping prokaryotic type IIA topoisomerases (DNA gyrase and TOPO IV), resulting in irreversible topoisomerase cleavage complexes. However, current U.S. Food and Drug Administration (FDA) guidance reserves...

Published: 4/8/2024 | Inventor(s): Yves Pommier, Shar-yin Huang, Brianna Mitchell

Keywords(s): Antibacterial, Antibiotic Adjuvants, Antibiotic Resistance, DNA gyrase, Exonuclease VII, ExoVII, Infection, Pommier, Quinolone, TOPO IV, Topoisomerase Poisons

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Therapeutics

Use of Acetalax for Treatment of Triple Negative Breast Cancer

Abstract: Triple negative (progesterone receptor (PR)-, estrogen receptor (ER)-, human epidermal growth receptor 2 (HER2)-) breast cancer (TNBC) is an aggressive subtype that affects 15-20% of the 1.7 million cases of breast cancer occurring annually. Currently, standard treatments of TNBC include cytotoxic chemotherapies, surgery, and radiation. However,...

Published: 4/8/2024 | Inventor(s): William Reinhold, Matthew Garnett, Vinodh Rajapakse, Yves Pommier, Augustin Luna

Keywords(s): Acetalax, Oxyphenisatin Acetate, Pommier, TNBC, Triple Negative Breast Cancer, Uterine Cancer

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology

Novel Furoquinolinediones as Inhibitors of TDP2 and Their Potential Use to Treat Cancer

Abstract: Tyrosyl-DNA phosphodiesterase 2 (TDP2) is an enzyme that playings a critical role in repairing nucleic acid lesions, namely by repairing trapped DNA cleavage complexes. TDP2 repairs topoisomerase (TOP2)-mediated DNA damage induced by chemotherapeutic agents and removes endogenous TOP2-DNA cleavage complexes. Further, TDP2 deficiency potentiates...

Published: 4/8/2024 | Inventor(s): Christophe Marchand, Lin-kun An, Yves Pommier

Keywords(s): CANCER, Combination Therapies, Pommier, therapeutic, Topoisomerase 2 (TOP2), Tyrosyl-DNA Phosphodiesterase 2 (TDP) Inhibitors

Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics

Topoisomerase III (TOP3) Inhibitors and Antiviral Compounds based on Cyanine Dyes

Topoisomerase 3B (TOP3B) is the only topoisomerase that can act on RNA as well as DNA, and thus has been a target of interest for the development of cancer therapies and RNA viral infection therapies. In the context of cancer, TOP3B is not an essential gene, but a subset of cancer cells with pre-existing genome instability are particularly vulnerable...

Published: 4/8/2024 | Inventor(s): Yves Pommier, Shar-yin Huang, Wenjie Wang, Weidong Wang, Sourav Saha, Tianyi Zhang, Mariano Garcia-Blanco, Pei-Yong Shi, Yuk-Ching Tse-Dinh, Debbie Kennedy-Boone

Keywords(s): CANCER, Cyanine Dye, NIA, Pommier, SARS-CoV-2, TOP, TOP3, TOP3 Inhibitor, TOPOISOMERASE, Topoisomerase III, Topoisomerase Inhibitor, viral infection, Wang

Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Infectious Disease, TherapeuticArea > Oncology